SOT Stock Overview
A pharmaceutical company, engages in the manufacturing and sale of medicines in Morocco.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for SOT from our risk checks.
Société de Therapeutique Marocaine S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.م949.00 |
| 52 Week High | د.م1,075.00 |
| 52 Week Low | د.م881.00 |
| Beta | -0.11 |
| 11 Month Change | 2.04% |
| 3 Month Change | 0.42% |
| 1 Year Change | -6.96% |
| 33 Year Change | -38.70% |
| 5 Year Change | 153.07% |
| Change since IPO | 611.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| SOT | MA Pharmaceuticals | MA Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | 2.2% |
| 1Y | -7.0% | 3.9% | 20.6% |
Return vs Industry: SOT underperformed the MA Pharmaceuticals industry which returned 6.5% over the past year.
Return vs Market: SOT underperformed the MA Market which returned 21% over the past year.
Price Volatility
| SOT volatility | |
|---|---|
| SOT Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in MA Market | 8.1% |
| 10% least volatile stocks in MA Market | 2.4% |
Stable Share Price: SOT has not had significant price volatility in the past 3 months compared to the MA market.
Volatility Over Time: SOT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 1,179 | Lamia Tazi | www.sothema.com |
Société de Therapeutique Marocaine S.A., a pharmaceutical company, engages in the manufacturing and sale of medicines in Morocco. It offers products in various therapeutic areas, including allergology, oncology, cardiology, dental, dermatology, endocrinology, gastroenterology, gynecology, ophthalmology, ENT, pediatric, pulmonology, reanimation, rheumatology, central nervous system (CNS), and urology, as well as antibiotics and other generic drugs. The company also provides its products in various forms, such as tablets, capsules, pouches, syrups, suspensions, powders, collyriums, suppositories, creams and pomades, injectable solutions, and self-injectable syringes.
Société de Therapeutique Marocaine S.A. Fundamentals Summary
| SOT fundamental statistics | |
|---|---|
| Market cap | د.م6.83b |
| Earnings (TTM) | د.م280.52m |
| Revenue (TTM) | د.م2.63b |
24.4x
P/E Ratio2.6x
P/S RatioIs SOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOT income statement (TTM) | |
|---|---|
| Revenue | د.م2.63b |
| Cost of Revenue | د.م1.44b |
| Gross Profit | د.م1.19b |
| Other Expenses | د.م907.91m |
| Earnings | د.م280.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 38.96 |
| Gross Margin | 45.19% |
| Net Profit Margin | 10.67% |
| Debt/Equity Ratio | 38.5% |
How did SOT perform over the long term?
See historical performance and comparison